Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (2): 196-203.doi: 10.12092/j.issn.1009-2501.2021.02.011

Previous Articles     Next Articles

Treatment strategies of FGFR molecular alterations in lung squamous cell carcinoma

XIE Rongrong 1, CHEN Zhi 1, YANG Yu 2, XIE Raoying 3, LI Pingping 1, SUN Shuangshuang 1, CHEN Wenjun1   

  1. 1 Department of Radiotherapy and Chemotherapy of the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China; 2 Department of Medical Oncology of Wenzhou Geriatric Hospital, Wenzhou 325000, Zhejiang, China; 3 Department of Radiotherapy and Chemotherapy of the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China
  • Received:2020-08-31 Revised:2021-01-02 Online:2021-02-26 Published:2021-03-04

PDF (PC)

152

Abstract: Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related death. Molecular targeted therapy for lung cancer, especially non-squamous non-small cell lung cancer, has developed rapidly and achieved good results. Several studies have found that fibroblast growth factor receptor (FGFR) signaling supports cancer cell proliferation and stimulates angiogenesis through different mechanisms, which plays a role in the development and progression of several tumors. This indicates that the inhibitions of FGFR signaling pathway may inhibit the proliferation of cancer cells. Dysregulation of FGFR signaling has been observed in some types of malignancy, including lung squamous cell carcinoma (LUSC), making FGFR a potential therapeutic target for LUSC. This review focuses on the role of FGFR signaling and some FGFR inhibitors in LUSC.

Key words: lung squamous cell carcinoma, fibroblast growth factor receptor, targeted therapies

CLC Number: